Miracle Mile Advisors LLC Buys New Stake in Becton Dickinson and Co (BDX)

Miracle Mile Advisors LLC bought a new position in shares of Becton Dickinson and Co (NYSE:BDX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,310 shares of the medical instruments supplier’s stock, valued at approximately $295,000.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Becton Dickinson and by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 21,666,262 shares of the medical instruments supplier’s stock valued at $5,654,895,000 after acquiring an additional 283,433 shares during the last quarter. Vanguard Group Inc boosted its holdings in shares of Becton Dickinson and by 1.3% in the 3rd quarter. Vanguard Group Inc now owns 21,666,262 shares of the medical instruments supplier’s stock valued at $5,654,895,000 after acquiring an additional 283,433 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Becton Dickinson and by 1.3% in the 3rd quarter. BlackRock Inc. now owns 19,029,060 shares of the medical instruments supplier’s stock valued at $4,966,582,000 after acquiring an additional 253,041 shares during the last quarter. FMR LLC boosted its holdings in shares of Becton Dickinson and by 8.0% in the 3rd quarter. FMR LLC now owns 17,354,031 shares of the medical instruments supplier’s stock valued at $4,529,401,000 after acquiring an additional 1,286,579 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of Becton Dickinson and by 0.8% in the 3rd quarter. Wells Fargo & Company MN now owns 3,565,101 shares of the medical instruments supplier’s stock valued at $930,491,000 after acquiring an additional 27,188 shares during the last quarter. 83.79% of the stock is currently owned by institutional investors.

BDX opened at $239.19 on Wednesday. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 0.90. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87. The firm has a market capitalization of $64.94 billion, a P/E ratio of 21.72, a PEG ratio of 1.74 and a beta of 1.21.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.93. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.88%. The firm had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the previous year, the business posted $2.40 EPS. The business’s revenue was up 39.0% compared to the same quarter last year. As a group, equities research analysts forecast that Becton Dickinson and Co will post 12.11 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Monday, December 31st. Investors of record on Monday, December 10th were paid a $0.77 dividend. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a dividend yield of 1.29%. The ex-dividend date of this dividend was Friday, December 7th. Becton Dickinson and’s payout ratio is currently 27.97%.

In related news, SVP Charles R. Bodner sold 2,080 shares of the business’s stock in a transaction on Friday, November 16th. The shares were sold at an average price of $245.83, for a total value of $511,326.40. Following the completion of the transaction, the senior vice president now directly owns 4,497 shares in the company, valued at approximately $1,105,497.51. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP James W. Borzi sold 5,887 shares of the business’s stock in a transaction on Friday, November 30th. The shares were sold at an average price of $252.37, for a total transaction of $1,485,702.19. Following the completion of the transaction, the executive vice president now owns 6,013 shares of the company’s stock, valued at $1,517,500.81. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,795 shares of company stock valued at $19,571,318. Company insiders own 0.12% of the company’s stock.

Several analysts have recently commented on BDX shares. Citigroup dropped their price objective on shares of Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating on the stock in a report on Tuesday, November 13th. Deutsche Bank started coverage on shares of Becton Dickinson and in a report on Thursday, December 6th. They issued a “buy” rating and a $280.00 price objective on the stock. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $243.00 price objective on the stock in a report on Tuesday, January 8th. TheStreet downgraded shares of Becton Dickinson and from a “b+” rating to a “c+” rating in a report on Friday, December 7th. Finally, Morgan Stanley dropped their price objective on shares of Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 2nd. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $251.17.

TRADEMARK VIOLATION NOTICE: This story was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2019/01/23/miracle-mile-advisors-llc-buys-new-stake-in-becton-dickinson-and-co-bdx.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: What is a Swap?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply